Teladoc Health: Cheap Valuation Is Fair Due To Fundamental Flaws


  • Teladoc Health is undervalued due to fundamental flaws like decelerating revenue growth and intense competition in the telehealth market.
  • The company has not achieved operating profitability and faces challenges with its business model and high expenses.
  • Despite its cheap valuation, TDOC’s strategic weaknesses are reflected in its stock price.

Woman talking to doctor on video call

The Good Brigade/DigitalVision via Getty Images

My thesis

Despite extreme undervaluation based on valuation ratios and the DCF model, I am neutral about Teladoc Health (NYSE:TDOC) and assign it a Hold rating. Deep undervaluation is justified by multiple fundamental

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *